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ABSTRACT
Objective: The combination of paclitaxel-cisplatin regimen is one of the chemotherapy regimens used at Sanglah General Hospital, Denpasar. Cisplatin 
is a potent chemotherapeutic agent, but the nephrotoxic effects of cisplatin reported that research is needed to see the toxic effect on the kidneys 
before and after 6 series of paclitaxel-cisplatin chemotherapy. Toxicity assessment of the chemotherapy can be observed by evaluating kidney function 
from monitoring both blood urea nitrogen (BUN) and creatinine serum value.
Methods: The research was conducted as an observational study using a prospective cohort method. The research was conducted from January 2016 
to June 2016. Patients’ follow-up was conducted from the first until the last series of chemotherapy. The data were statistically analyzed with STATA 
version 14 with paired t-test when the data were normally distributed or the data were analyzed with Wilcoxon test when they were not normally 
distributed.
Results: A total of seven patients were evaluated with both their BUN and creatinine serum values during six series of chemotherapy. Statistically, the BUN 
and creatinine serum values before the first and after the last paclitaxel-cisplatin chemotherapy series are not statistically significantly different (p>0.05).
Conclusion: There are no significant changes of both BUN and creatinine serum values before the first and after the last paclitaxel-cisplatin 
chemotherapy series in patients with stadium IIB-IIIB squamous cell cervical cancer. Research with larger sample size is essential to provide optimal 
information for other health-care professionals.
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INTRODUCTION
Cervical cancer is the second most prominent cancer in the world. Data 
based on preliminary studies conducted by researchers at Sanglah 
General Hospital (GH) in December 2015 show that there were 2157 
cervical cancer patients in 2013 and this number increased by 61% 
within a year to 3473 cervical cancer patients in 2014. This number 
keeps on increasing annually, in which in 2015, the number of cervical 
cancer patients at Sanglah GH was recorded at 4797, with the most 
gynecologic ferocity indicated as squamous cell cervical cancer.
One therapeutic procedure for cervical cancer is chemotherapy. Six-
cyclic chemotherapy will provide better result toward the cancer 
victims than three-cyclic chemotherapy. However, the former would 
undeniably result in higher toxicity level compared to the latter one. 
This is in concord to Colleani et al’s. (2002) research findings, in 
which breast cancer patients who went through less chemotherapy 
procedures could significantly reduce the toxic risk. As a result, there 
needs to be a study about six-cyclic chemotherapy toxic implication 
toward cervical cancer patients [1].
Cisplatin is the nephrotoxic chemotherapy agent. Platinum content 
in cisplatin has the role of inducing nephrotoxicity due to glomerular 
damage [2]. Nephrotoxic effect by cisplatin agent could be monitored 
from the value of blood urea nitrogen (BUN) and creatinine serum used 
as the indicator of the patients’ kidney function. The increase of BUN 
level and creatinine serum in patients could be utilized to assess the 
degree of kidney dysfunction as the side effect of chemotherapy [3]. 
Thus, the focus of this research would be to determine whether or not 
there is a toxicity difference in patients’ kidney function indicated by 
creatinine serum and BUN before the first chemotherapy series and 
after the sixth chemotherapy series.
METHODS
The research was conducted in Sanglah GH, Denpasar, after acquiring ethical 
clearance permission from the Ethical Research Committee of Medical 
Faculty, Udayana University. It is an observational research utilizing case 
study method at Obstetrics and Gynecology Clinics, Sanglah GH, Denpasar, 
Bali. This method was carried out by following up patients beginning from 
the first chemotherapy to the sixth chemotherapy cycle. The data were 
taken from before and after chemotherapy Cycles I and VI. Selection of 
patients was based on the following criteria: New patients with squamous 
cell cervical cancer stadium IIB-IIIB; patients who agree to follow-up 
research by filling informed consent; clinical conditions and laboratory 
results that fulfill the requirements to get chemotherapy; and patients who 
could go through the entire range of chemotherapy Cycles I-III. Exclusion 
criteria of the research were patients whose progress could not be followed 
up for reasons such as death, financial problems, and loss of contact (lost to 
follow-up).
The data of creatinine serum and BUN were measured before 
chemotherapy Cycle I and after chemotherapy Cycle VI. Furthermore, all 
data obtained have undergone a normality test by first using Shapiro–
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Wilk test. If the data were normal, paired t-test will be tested. If the data 
were not normal, the data would be analyzed by Wilcoxon test. The 
significantly different impact on creatinine serum and BUN in patients 
was characterized by a value of p<0.05.
RESULTS
Within the period of January until June 2016, there were seven 
patients acquired as the research patients. The limited number 
of research patients was due to time limitation and the limited 
number of patients who fulfilled both the inclusion and exclusion 
criteria as well as the ones who could complete the six chemotherapy 
series.
Patients’ characteristics
The seven research patients’ characteristics were categorized into age, 
marital age, marital status, educational level, occupational status, area 
of origin, stadium of disease, and insurance status (Table 1).
Creatinine serum value differential test
Analysis of creatinine serum value before the first chemotherapy 
and after the sixth chemotherapy was administered to determine the 
difference of creatinine serum value before and after the six series of 
chemotherapy. The difference of creatinine serum value before and 
after paclitaxel-cisplatin chemotherapy will be deemed as meaningful 
if the final value reaches *p<0.05. Meaningful value of the increased 
creatinine serum after paclitaxel-cisplatin chemotherapy will be used 
as the indicator of kidney dysfunction side effect.
To determine the range of data distribution, normalized test was 
conducted to the value of creatinine serum before the first series 
of chemotherapy and after the sixth series of paclitaxel-cisplatin 
chemotherapy, using Shapiro-Wilk method for the first series. The data 
of creatinine serum level before the first series of chemotherapy have 
a normal distribution. Meanwhile, the level of creatinine serum before 
the sixth series of chemotherapy has abnormal distribution; therefore, 
it has to be analyzed with Wilcoxon test. The results of the difference of 
creatinine serum value before the first series of chemotherapy and after 
the sixth series of paclitaxel-cisplatin chemotherapy with Wilcoxon test 
are shown in Table 2.
Based on the analytical results shown in Table 2, there is no meaningful 
difference of creatinine serum value before the chemotherapy series I 
and after paclitaxel-cisplatin chemotherapy series VI. The median value 
shows that there is a decrease of creatinine serum level after paclitaxel-
cisplatin chemotherapy series VI although it is not meaningful 
(*p>0.05).
BUN value differential test
Data of BUN value were tested with Shapiro-Wilk normalized test to see 
the data distribution. Its value before the first chemotherapy series has 
normal distribution. Meanwhile, its value after the sixth chemotherapy 
series has abnormal distribution; therefore, it has to be analyzed with 
Wilcoxon test. The results of the difference of creatinine BUN value before 
the first chemotherapy series and after the sixth series of paclitaxel-
cisplatin chemotherapy with Wilcoxon test are shown in Table 3.
Based on analytical results of Table 3, there is no meaningful difference 
of BUN value before the chemotherapy series I and after paclitaxel-
cisplatin chemotherapy series VI. The mean value shows that there 
is an increase of BUN value after paclitaxel-cisplatin chemotherapy 




From Table 1, it could be deduced that all of the cervical cancer patients 
are all above 30 years old. This is in align with literature sources that 
explain about how cervical cancer develops in those who are in their 
30s or more [4]. Nevertheless, it could also be diagnosed in female 
populations who are in their 20s and teens [5].
If linked to marital age, it could be inferred that those who have their 
first coitus before reaching the 20s has a risk of infecting cervical cancer. 
HPV infection as the most common cause of cervical cancer would be 
identified in between 18-30 years of age which is a few years after the 
first coitus took place [4].
Table 1: Patients characteristics












Not married 0 (0)
Educational level
No formal education 1 (14.28)
Elementary 3 (42.86)
Middle school 2 (28.57)
High school 1 (14.28)
Occupational status







East Lombok, NTB 2 (28.57)
Sulawesi 1 (14.28)





BPJS* Umum# 5 (71.43^)
BPJS Askes Wajib# 1 (14.28)
BPJS Jamkesmas# 1 (14.28)
*BPJS (Badan Penyelenggara Jaminan Sosial) is a government-sponsored 
health insurance program in Indonesia. #All of the terms (Umum, Askes Wajib, 
Jamkesmas) refer to different types of government organizations that will be 
the guarantor of the insurance
Table 2: Analytical results of creatinine serum value difference before the first series of chemotherapy and after the sixth series of 
chemotherapy with Wilcoxon test
Chemotherapy N Creatinine serum p
Median (ng/L) Minimum (ng/L) Maximum (ng/L)
Before chemotherapy I 7 0.800 0.6 1.1 0.600
After chemotherapy VI 7 0.700 0.52 2.19
N: Sample’s quantity, P: Level of meaningfulness. if p<0.05, the difference is meaningful
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If observed from educational level, occupational status, and area of 
origin, most patients have not received adequate information about 
both the risk and precautionary actions in preventing cervical cancer. 
This means that more educational programs are necessary in order to 
increase the awareness about the danger of cervical cancer.
All the research participants were all in stadium IIIB. All of them started 
their treatment at Obstetrics and Gynecology Clinics of Sanglah GH 
after been diagnosed at stadium IIIB. This might occur due to the fact 
that there were no specific symptoms during the early stages of HPV 
virus infection. Patients started their treatment late after experiencing 
symptoms such as bleeding and continuous leukorrhea which were 
indeed developed in later stages. Therefore, early preventive actions of 
cervical cancer have to be socialized to communities so that successful 
cervical cancer safeguards could be achieved.
The whole research patients were using Jaminan Kesehatan Nasional 
(JKN), one of the Indonesia’s government health insurance programs. 
From the data, all the patients in this research were using BPJS Kesehatan 
through JKN program, either participant paid their own premi or premi 
paid by the government for less-affluent people. Social Health Insurance 
is health financing system in a country where revenue typically comes 
from membership contributions, employer contributions, government 
subsidies and interest payments on any accumulated funds (Ole et al., 
2010). The concept of social health insurance is applied by JKN. The 
main principle of social health insurance is to prevent households not to 
fall into poverty because they have to pay the cost of expensive medical 
treatment [7]. This program was very helpful for the patients who were 
having their treatments since they are costly.
Chemotherapies would cause side effect such as toxicity. Kidney is one 
of the organs that could be used in monitoring the toxic implication 
caused by chemotherapies. Cytotoxic medicine is commonly secreted 
through kidney, whereas the parameters to determine kidney function 
are the value of BUN and creatinine serum [8].
Creatinine serum value differential test
The examination of blood creatinine could be utilized to determine 
glomerulus’ filtration capacity through creatinine clearance test. The 
level of blood creatinine could also provide the information about 
the severity level of kidney dysfunction. The value would be higher in 
deteriorating kidney function [9].
The normal value of creatinine serum according to Sanglah GH Standard 
Operational Procedure is 0.50-0.90 mg/dL. In this research, the analytical 
results of Table 2 show that there is no significant increase in creatinine 
serum value before chemotherapy series I and after chemotherapy 
series VI (*p>0.05). Six out of the seven patients in this research showed 
stable creatinine serum value within normal range after the six series of 
paclitaxel-cisplatin chemotherapy. This is in accordance to the research 
of Kidera et al. (2014) which stated that there is no significant correlation 
between cisplatin chemotherapy and kidney’s toxicity in which the value 
is p=0.373 (*p>0.05). Another research in six squamous cell cervical 
cancer stadium IIB-IIIB cases using carboplatin-paclitaxel regimen also 
does not show significant difference toward creatinine serum value after 
3 series of chemotherapy (*p>0.05) [11]. However, this is in contrast to 
research conducted by Arankumar et al., (2012) in which the value of 
creatinine serum increased significantly from BUN value after undergoing 
cisplatin chemotherapy. This might indicate the possibility of severe 
nephrotoxicity [12]. The contrasting result obtained by this research 
compared to other literature resources might be triggered by the lack of 
sufficient samples to provide significant statistics. Meanwhile, the usage 
of paclitaxel tends to cause myelosuppression instead of deteriorating 
kidney function [13].
One out of seven patients in this research experienced the increase in 
creatinine serum value beyond the normal value. The creatinine serum 
value of this patient before the chemotherapy Series I was 0.8 mg/dL 
and it increased 2.7 times to 2.19 mg/dL. The increase of creatinine 
serum value might indicate the occurrence of the patient’s deteriorating 
kidney function in excreting body’s waste. This condition might be the 
result of cisplatin’s side effect. One of them is nephrotoxicity that may 
lead to kidney failure. Cisplatin nephrotoxicity works by accumulating 
cisplatin in kidney cells which will then trigger the apoptosis of the 
cells [2]. The existence of patient with deteriorating kidney function by 
cisplatin chemotherapy shows the importance of assessing individual 
patient’s response toward chemotherapy. If unwanted response such as 
the increase of creatinine serum value beyond normal value takes place, 
it is advisable to adjust the chemotherapy dosage in accordance to the 
patient’s GFR value [14].
That is why, it is necessary to keep tabs on creatinine serum value 
before chemotherapy, during chemotherapy, and after chemotherapy so 
that the risk of unwanted incidents such as severe kidney failure could 
be prevented. This would in return guarantee the safety of patients 
from side effects that could further exacerbate the life quality of cervical 
cancer patients.
BUN value differential test
One of the kidney essential functions is to eliminate potential toxic 
substances such as urea from our bodies. In case of deteriorating kidney 
function, the BUN value would increase. BUN test, which measures urea 
nitrogen, is utilized as the index indicator of glomerulus function in 
producing and excreting urea. Consequently, BUN measurement would 
be the indicator of kidney function [3].
BUN value measurement would be administered before and after every 
series of chemotherapy. Analysis of BUN value before and after the first 
series of chemotherapy until the sixth series of chemotherapy would 
be administered to determine the difference of BUN value in every 
series of chemotherapy. Likewise, the analysis of BUN value before 
the first chemotherapy and after the sixth chemotherapy would also 
be administered to determine the difference of BUN value before and 
after the six series of chemotherapy. The difference of BUN value before 
and after paclitaxel-cisplatin chemotherapy would be considered as 
meaningful if the value is *p<0.05. The increase of BUN value after 
paclitaxel-cisplatin chemotherapy would be the indicator of kidney 
dysfunction side effect.
Referral normal BUN value according to Sanglah GH Standard 
Operational Procedure is 8.00-23.00 mg/dL. BUN value is not only 
affected by kidney function. Another factor contributing to the change 
of BUN value is protein intake, which is related to how urea is the waste 
product of protein metabolism. Thus, the level of patients’ protein 
intake would also affect their BUN value. Besides that, BUN value is also 
affected by liver because liver is responsible for the conversion of amino 
acid into urea [3].
Table 3: Analytical results of BUN value difference before the first series of chemotherapy and after the sixth series of chemotherapy 
with Wilcoxon test
Chemotherapy N BUN p
Median (ng/L) Minimum (ng/L) Maximum (ng/L)
Before chemotherapy I 7 10.00 9.00 16.00 0.125
After Chemotherapy VI 7 13.00 10.00 26.00
N: Sample’s quantity, p: Level of meaningfulness, BUN: Blood urea nitrogen. if p<0.05, the difference is meaningful
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The level of BUN before chemotherapy I and after chemotherapy VI based 
on Table 3 of this research shows no significant difference statistically. 
This is in concord to the research of Arunkumar et al. (2012) that 
stated out of 18 patients who underwent cisplatin chemotherapy with a 
dosage of 40-50 mg/m2 for 5 series showed no significant difference in 
BUN value before and after 5 series of chemotherapy (*p=0.292) [12]. 
On the other hand, research conducted by Tazcan et al. (2013) involving 
52 cancer patients that have undergone platinum-based chemotherapy 
shows a significant increase in BUN value (p<0.05) after going through 
cisplatin chemotherapy (Tazcan et al., 2013). This contrast might be 
due to the difference of patients’ number involved in the research and 
thus affecting the significant result.
On this research, there was one patient who experienced the increase of 
BUN value beyond the normal value. The patient’s BUN level which was 
9.00 mg/dL before chemotherapy series I has increased to 26.00 mg/dL 
after going through 6 chemotherapy sessions. The increase of BUN 
value beyond normal value might indicate the kidney’s deteriorating 
capacity in excreting body’s waste. The patient’s deteriorationg kidney 
function might be the result of adverse drug reaction caused by the 
usage of cisplatin. According to Miller et al., (2010) platinum content in 
cisplatin plays a role in inducing nephrotoxicity as a consequence of the 
glomerular damage [2]. Since the possibility for patients to suffer from 
deteriorating kidney function due to cisplatin chemotherapy exists, it is 
necessary to observe every patient’s response towards chemotherapy. 
Adjustment of chemotherapy dosage in accordance to patient’s GFR 
value might be considered if cisplatin chemotherapy has led to the 
deterioration of kidney function. 
The fact that some patients suffered from deteriorating kidney function 
after undergoing cisplatin chemotherapy procedure shows that it is 
essential to determine every patient’s response toward chemotherapy. 
It is vital to accommodate chemotherapy dosage according to each 
patient’s GFR value in case of the occurrence of symptom like the 
increase of BUN value beyond the normal one [14].
Therefore, it’s advisable to keep track on BUN value before, after, and 
during chemotherapy procedure to avoid negative outcome like severe 
kidney failure. By applying this, the risk of cervical cancer patients 
suffering from unnecessary side effects that could potentially worsen 
their life quality would be minimized.
CONCLUSION
There is no significant difference in both BUN value and creatinine 
serum value before chemotherapy series I and after paclitaxel-cisplatin 
chemotherapy series VI in squamous cell cervical cancer patients 
stadium IIB-IIIB at Sanglah GH.
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